Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0O3DK
|
|||
Former ID |
DCL000829
|
|||
Drug Name |
GTP-010
|
|||
Indication | Dyspepsia [ICD-11: MD92] | Phase 2 | [1] | |
Irritable bowel syndrome [ICD-11: DD91.0; ICD-10: K55-K64, K58] | Phase 2 | [1] | ||
Company |
Gastrotech Pharma
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.